ZD-0892 AstraZeneca.
ZD-0892, a neutrophil elastase inhibitor, is under development by AstraZeneca as a potential treatment for chronic obstructive pulmonary disease (COPD) and peripheral vascular disease (PVD). It is in phase I clinical trials for these two indications [315489]. The compound was originally under investigation for the potential treatment of asthma, but development was discontinued for this indication [266604]. The compound is the follow-up to ZD-8321 (qv) [336599].
Nagoya University School of Medicine, Second Department of Internal Medicine, 86 Toki-Cho, Mizunami City, Gifu Prefecture, Japan. ohbayasi@nn.iij4u.or.jp
H
H
Ohbayashi
D000818:Animals; D018927:Anti-Asthmatic Agents / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D001249:Asthma / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D006801:Humans; D019272:Leukocyte Elastase / Q000037:antagonists & inhibitors*; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D013329:Structure-Activity Relationship; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity
D018927:Anti-Asthmatic Agents; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors; D011758:Pyrroles; D013449:Sulfonamides; C114412:ZD 0892; D019272:Leukocyte Elastase